$EOLS "Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Evolus shares, saying there is likely good news driving the stock 40%-50% higher..," at the time "Evolus confirmed there is no ITC preliminary decision yet, she says, but adds that since Medytox shares are also higher, it could mean that there has been a settlement between the companies, removing a significant overhang on Evolus shares. Now, The Barclays analysts just came out and said the the decision in Korea "has no implications for Evolus". So who is right?